Mar 24, 2020 8:00 am EDT Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
Mar 18, 2020 4:01 pm EDT Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Mar 17, 2020 8:00 am EDT Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion
Mar 11, 2020 4:30 pm EDT Capricor Therapeutics to Present Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Update on March 18
Dec 19, 2019 1:14 pm EST Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
Dec 17, 2019 1:52 pm EST Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market
Nov 07, 2019 4:00 pm EST Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
Nov 01, 2019 9:00 am EDT Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7
Oct 21, 2019 9:25 am EDT Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Oct 07, 2019 6:30 am EDT Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months